Increasing the Time Interval Suppresses Adverse Effects After Concomitant Use of Nafamostat Mesylate and Levocarnitine in Dialysis Patients: Case Series
Lili Jiang1, Jiaoyan Chen1, Jurong Yang1
1Department of Nephrology, The Third Affiliated Hospital of Chongqing Medical University (FangDa Hospital), Chongqing, China.
Purpose:
This is a series of reports describing how increasing the time interval between the administration of nafamostat mesylate (NM) and levocarnitine can suppress adverse reactions in maintenance hemodialysis patients after medication.
Methods:
Clinical assessments and medical record collection were conducted by nephrologists and nurses, while laboratory tests were performed by specialist doctors.
Findings:
Increasing the time interval between NM and levocarnitine administration (15-25 minutes) reduced adverse drug reactions, including nausea and vomiting, in 4 patients.
Implications:
This may provide clinical doctors with new insights and research directions when using levocarnitine and NM for dialysis treatment.
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Therapeutic Drug Monitoring: Affecting Factors
Time Course of Drug Effect
